Holen Sie sich die Stockscreener-App
1.27
3.05%
-0.04
Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten
Activity Recap: Is Telomir Pharmaceuticals Inc stock influenced by commodity pricesCPI Data & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Valuation Update: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Selloffs & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Rating Upgraded by Wall Street Zen - Defense World
Is Telomir Pharmaceuticals Inc. stock a good dividend stockJuly 2025 Gainers & Verified Chart Pattern Signals - mfd.ru
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 4.2% – Should You Sell? - Defense World
Telomir Sets Vote on Transformative TELI Merger and Governance Changes - TipRanks
Telomir reveals promising preclinical data for Telomir-Zn - TipRanks
Telomir Pharmaceuticals demonstrates broad tumor cell mortality in human triple-negative breast cancer models - marketscreener.com
Telomir Pharmaceuticals Inc's latest research shows that the company has achieved extensive tumor cell death rates in human triple-negative breast cancer experimental models. - Bitget
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - Columbus Ledger-Enquirer
Telomir Pharmaceuticals, Inc. Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - marketscreener.com
Experimental breast cancer drug triggers iron-dependent tumor cell death - Stock Titan
Investment Report: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
What are the risks of holding Telomir Pharmaceuticals Inc.Trade Exit Summary & Entry Point Confirmation Signals - mfd.ru
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Telomir Pharmaceuticals Inc. a top pick in the sectorTrade Signal Summary & Weekly Momentum Picks - mfd.ru
Will Telomir Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Growth Report & Community Supported Trade Ideas - mfd.ru
Can Telomir Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Sentiment & Precise Swing Trade Alerts - mfd.ru
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - The Asheville Citizen Times
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging - ACCESS Newswire
What are the risks of holding Telomir Pharmaceuticals IncChart Signals & Daily Growth Stock Investment Tips - baoquankhu1.vn
Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1 - TipRanks
Experimental Telomir-Zn compound rebalances metals tied to cancer and aging - Stock Titan
Telomir Pharmaceuticals Reports New Cellular Data on Epigenetic Modulation - TradingView
Setup Watch: Can Telomir Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Selloffs & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Wrap: Is SIGA in a consolidation phasePortfolio Update Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Is Telomir Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Review & Growth Focused Stock Reports - mfd.ru
Insider Buy: How does Telomir Pharmaceuticals Inc compare to its peersRate Hike & Daily Profit Focused Screening - baoquankhu1.vn
Stock Analysis: How volatile is Telomir Pharmaceuticals Inc stockQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Market Outlook: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockWeekly Gains Report & Stepwise Trade Execution Plans - baoquankhu1.vn
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR) - Defense World
Gainers Report: What are the risks of holding Telomir Pharmaceuticals Inc2025 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Review & Low Risk Entry Point Tips - baoquankhu1.vn
How does Telomir Pharmaceuticals Inc. compare to its peersJuly 2025 Weekly Recap & Technical Pattern Based Signals - bollywoodhelpline.com
Rodman & Renshaw initiates Telomir Pharma stock with Buy rating By Investing.com - Investing.com Canada
Aug Shorts: Is ImmuCell Corporation forming a bullish divergenceEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Telomir Pharmaceuticals Received Notice of Noncompliance - TradingView
Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Published on: 2026-01-10 12:17:57 - ulpravda.ru
Aug Movers: Why Telomir Pharmaceuticals Inc. stock is recommended by analystsGlobal Markets & Real-Time Market Trend Scan - ulpravda.ru
Is Telomir Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Outlook & Advanced Swing Trade Entry Alerts - Улправда
Why retail investors favor Telomir Pharmaceuticals Inc. stockQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - Улправда
Trend Review: Why retail investors favor Telomir Pharmaceuticals Inc stockEarnings Growth Report & Step-by-Step Trade Execution Guides - Bộ Nội Vụ
Can Telomir Pharmaceuticals Inc. stock sustain revenue growthMerger & Acquisition Updates & Build Wealth With Expert Timing Advice - Улправда
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models - The Florida Times-Union
How Telomir Pharmaceuticals Inc. stock reacts to inflationary pressuresLow Risk Investment Ideas & Minimal Investment Portfolio Growth - ulpravda.ru
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models - Investing.com Australia
Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It - Benzinga
1.18%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):